Home / Science / ADHD Drug Trial for Alzheimer's Breakthrough

ADHD Drug Trial for Alzheimer's Breakthrough

22 Oct

Summary

An ADHD medication will be trialed as an Alzheimer's treatment.
The pioneering NHS trial will test atomoxetine's potential.
Dementia research is a national priority, according to Burnham.

In a pioneering initiative, an attention deficit hyperactivity disorder (ADHD) drug will be evaluated as a potential treatment for Alzheimer's disease within the NHS. Scientists are embarking on trials to determine if atomoxetine, commonly prescribed for ADHD, possesses properties beneficial for Alzheimer's patients.

This research marks a significant step in dementia care. Health secretary Burnham has emphasized the urgency and importance of this field, declaring dementia research a national priority. The trial signifies a dedicated effort to explore novel therapeutic strategies for a condition that affects millions worldwide.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.